Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma

被引:0
作者
Jan C. Buckner
Patrick A. Burch
Terrence L. Cascino
Judith R. O'Fallon
Bernd W. Scheithauer
机构
[1] Mayo Clinic and Mayo Foundation,Division of Medical Oncology
[2] Mayo Clinic and Mayo Foundation,Department of Neurology
[3] Mayo Clinic and Mayo Foundation,Cancer Center Statistics
[4] Mayo Clinic and Mayo Foundation,Section of Surgical Pathology
来源
Journal of Neuro-Oncology | 1998年 / 36卷
关键词
glioma; eflornithine; interferon; phase II; brain neoplasm;
D O I
暂无
中图分类号
学科分类号
摘要
Interferons alpha and beta have been reported to cause tumor regression in a small proportion of patients with recurrent glioma. Eflornithine, an irreversible inhibitor of ornithine decarboxylase, reduces cellular polyamine levels and has also been reported to cause tumor regression in patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. In vitro evidence suggests that interferon and eflornithine are synergistic. In this phase II trial, we investigated the combination of recombinant alpha interferon (36 × 106 units/m2 subcutaneously days 3 to 7) and eflornithine (2.25 g/m2 QID PO days 1 to 7) repeated every 28 days. All 29 patients entered in the study were evaluable for toxicity and efficacy. Toxicity consisted primarily of fever, chills, myalgia, weakness and fatigue as well as cortical dysfunction including somnolence, confusion, and exacerbation of underlying neurologic deficits. One patient died from cerebral herniation attributable to interferon. None of the patients experienced objective tumor regression. Seven patients (24%) were stable for more than six months, but the disease stability could also be explained by indolent underlying disease or inability to distinguish recurrent tumor from delayed radiation effects. Intermittent high-dose recombinant interferon alpha plus eflornithine demonstrated no definite antitumor effects in this trial.
引用
收藏
页码:65 / 70
页数:5
相关论文
共 50 条
[21]   Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial [J].
Morgan, R. J., Jr. ;
Synold, T. W. ;
Gandara, D. ;
Muggia, F. ;
Scudder, S. ;
Reed, E. ;
Margolin, K. ;
Raschko, J. ;
Leong, L. ;
Shibata, S. ;
Tetef, M. ;
Vasilev, S. ;
McGonigle, K. ;
Longmate, J. ;
Yen, Y. ;
Chow, W. ;
Somlo, G. ;
Carroll, M. ;
Doroshow, J. H. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) :373-378
[22]   Phase II study of topotecan in patients with recurrent malignant glioma [J].
Macdonald, D ;
Cairncross, G ;
Stewart, D ;
Forsyth, P ;
Sawka, C ;
Wainman, N ;
Eisenhauer, E .
ANNALS OF ONCOLOGY, 1996, 7 (02) :205-207
[23]   A PHASE-II TRIAL OF 5-FLUOROURACIL, LEUCOVORIN, AND RECOMBINANT INTERFERON-ALPHA-2B IN ADVANCED ADENOCARCINOMA OF THE PANCREAS [J].
SCHEITHAUER, W ;
PFEFFEL, F ;
KORNEK, G ;
MARCZELL, A ;
WILTSCHKE, C ;
FUNOVICS, J .
CANCER, 1992, 70 (07) :1864-1866
[24]   COMBINATION OF CISPLATIN AND INTERFERON-ALPHA-2A (ROFERON(R)-A) IN PATIENTS WITH NONSMALL CELL LUNG-CANCER (NSCLC) - AN OPEN PHASE-II MULTICENTER STUDY [J].
KATAJA, V ;
YAP, A .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (01) :35-40
[25]   PHASE-II STUDY OF 13-CIS-RETINOIC ACID AND INTERFERON-ALPHA-2A IN PATIENTS WITH ADVANCED SQUAMOUS-CELL LUNG-CANCER [J].
RINALDI, DA ;
LIPPMAN, SM ;
BURRIS, HA ;
CHOU, C ;
VONHOFF, DD ;
HONG, WK .
ANTI-CANCER DRUGS, 1993, 4 (01) :33-36
[26]   A PHASE-II TRIAL OF RECOMBINANT LEUKOCYTE INTERFERON PLUS DOXORUBICIN IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA [J].
FEUN, LG ;
SAVARAJ, N ;
HUNG, SE ;
REDDY, R ;
JEFFERS, L ;
BENEDETTO, P ;
LIVINGSTONE, AS ;
ARDALAN, B ;
LEVI, JU ;
PARKER, T ;
SCHIFF, ER .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1994, 17 (05) :393-395
[27]   Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: Clinical results and immunologic correlates of response [J].
Bukowski, RM ;
Olencki, T ;
Wang, Q ;
Peereboom, D ;
Budd, GT ;
Elson, P ;
Sandstrom, K ;
Tuason, L ;
Rayman, P ;
Tubbs, R ;
McLain, D ;
Klein, E ;
Novick, A ;
Finke, J .
JOURNAL OF IMMUNOTHERAPY, 1997, 20 (04) :301-311
[28]   RECOMBINANT ALPHA-2 INTERFERON GEL TREATMENT OF RECURRENT HERPES GENITALIS [J].
LEBWOHL, M ;
SACKS, S ;
CONANT, M ;
CONNOR, J ;
DOUGLAS, JM ;
ERON, L ;
MARLOWE, S ;
MENDELSON, J ;
CHEN, V ;
BRADSTREET, P ;
FEDORCZYK, D ;
TROUT, JR ;
PLASSE, T .
ANTIVIRAL RESEARCH, 1992, 17 (03) :235-243
[29]   Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma [J].
Nabors, L. B. ;
Supko, J. G. ;
Rosenfeld, M. ;
Chamberlain, M. ;
Phuphanich, S. ;
Batchelor, T. ;
Desideri, S. ;
Ye, X. ;
Wright, J. ;
Gujar, S. ;
Grossman, S. A. .
NEURO-ONCOLOGY, 2011, 13 (12) :1324-1330
[30]   PHASE-II STUDY OF RECOMBINANT ALPHA-INTERFERON AND RECOMBINANT INTERLEUKIN-2 IN METASTATIC BREAST-CANCER [J].
WALTERS, RS ;
THERIAULT, RL ;
HOLMES, FA ;
ESPARZA, L ;
HORTOBAGYI, GN .
JOURNAL OF IMMUNOTHERAPY, 1994, 16 (04) :303-305